Long term safety of etanercept in elderly subjects with rheumatic diseases

R. Fleischmann, S. W. Baumgartner, M. H. Weisman, T. Liu, B. White, P. Peloso

Research output: Contribution to journalArticle

Abstract

Objectives: To determine the long term safety profile of the tumour necrosis factor (TNF) antagonist etanercept in subjects with rheumatoid arthritis (RA), psoriatic arthritis (PsA), or ankylosing spondylitis (AS) aged ≥65 years in comparison with subjects aged

Original languageEnglish (US)
Pages (from-to)379-384
Number of pages6
JournalAnnals of the Rheumatic Diseases
Volume65
Issue number3
DOIs
StatePublished - Mar 2006
Externally publishedYes

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Fingerprint Dive into the research topics of 'Long term safety of etanercept in elderly subjects with rheumatic diseases'. Together they form a unique fingerprint.

  • Cite this

    Fleischmann, R., Baumgartner, S. W., Weisman, M. H., Liu, T., White, B., & Peloso, P. (2006). Long term safety of etanercept in elderly subjects with rheumatic diseases. Annals of the Rheumatic Diseases, 65(3), 379-384. https://doi.org/10.1136/ard.2005.035287